How to buy Intercept Pharmaceuticals stock (ICPT)

Intercept Pharmaceuticals is a biotechnology business based in the US. Intercept Pharmaceuticals shares (ICPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. Intercept Pharmaceuticals employs 341 staff and has a trailing 12-month revenue of around $317.7 million.

Our top picks for where to buy Intercept Pharmaceuticals stock

Buy Intercept Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Intercept Pharmaceuticals stock price (NASDAQ: ICPT)

Use our graph to track the performance of ICPT stocks over time.

Intercept Pharmaceuticals shares at a glance

• Key figures

Information last updated 2023-12-24.

Latest market close	$0.00
52-week range	$18.60 - $19.02
50-day moving average more info button	$16.63
200-day moving average more info button	$14.55
Wall St. target price	$19.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.09

Is it a good time to buy Intercept Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intercept Pharmaceuticals price performance over time

Historical closes compared with the close of $0 from 2023-11-20

1 week (2024-10-12)	N/A
1 month (2024-09-19)	N/A
3 months (2024-07-19)	N/A
6 months (2024-04-19)	N/A

1 year (2023-10-23)	-100.00%
2 years (2022-10-21)	-100.00%
3 years (2021-10-22)	17.13
5 years (2019-10-23)	68.92

Intercept Pharmaceuticals financials

Revenue TTM	$317.7 million
Operating margin TTM	1.85%
Gross profit TTM	$284.7 million
Return on assets TTM	-7.23%
Return on equity TTM	-64.02%
Profit margin	-19.39%
Book value	$1.72
Market Capitalization more info button	$794.7 million

TTM: trailing 12 months

Intercept Pharmaceuticals share dividends

We're not expecting Intercept Pharmaceuticals to pay a dividend over the next 12 months.

Intercept Pharmaceuticals share price volatility

Over the last 12 months, Intercept Pharmaceuticals's shares have ranged in value from as little as $18.6 up to $19.02. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intercept Pharmaceuticals's is 0.884. This would suggest that Intercept Pharmaceuticals's shares are less volatile than average (for this exchange).

Intercept Pharmaceuticals overview

Intercept Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors.

Frequently asked questions

null
What percentage of Intercept Pharmaceuticals is owned by insiders or institutions?
Currently 3.125% of Intercept Pharmaceuticals shares are held by insiders and 81.304% by institutions. How many people work for Intercept Pharmaceuticals?
Latest data suggests 341 work at Intercept Pharmaceuticals. When does the fiscal year end for Intercept Pharmaceuticals?
Intercept Pharmaceuticals's fiscal year ends in December. Where is Intercept Pharmaceuticals based?
Intercept Pharmaceuticals's address is: 10 Hudson Yards, New York, NY, United States, 10001 What is Intercept Pharmaceuticals's ISIN number?
Intercept Pharmaceuticals's international securities identification number is: US45845P1084 What is Intercept Pharmaceuticals's CUSIP number?
Intercept Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 45845P108